These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Zenhäusern R; Von Rohr A; Rufibach K; Solenthaler M; Meyer-Monard S; Gratwohl A; Hess U; Bargetzi MJ; Kovacsovic T; Leoncini L; Tobler A; Leuk Lymphoma; 2009 Jan; 50(1):133-6. PubMed ID: 19152171 [No Abstract] [Full Text] [Related]
30. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Tallman MS Leuk Lymphoma; 2011 Jun; 52 Suppl 2():65-8. PubMed ID: 21463116 [TBL] [Abstract][Full Text] [Related]
31. [Hairy cell leukemia treated with cladribine]. Ghanima W; Heldal D; Tjønnfjord GE Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051 [TBL] [Abstract][Full Text] [Related]
32. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine]. Zák P; Chrobák L; Dĕdic K; Podzimek K Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629 [TBL] [Abstract][Full Text] [Related]
33. Molecular study of hairy cell leukemia variant with biclonal paraproteinemia. Copeland AR; Bueso-Ramos C; Liu FJ; Kornblau SM; Huh YO; Albitar M Arch Pathol Lab Med; 1997 Feb; 121(2):150-4. PubMed ID: 9126043 [TBL] [Abstract][Full Text] [Related]
34. 2-Chlorodeoxyadenosine, a "novel" agent in the treatment of both lymphoid and myeloid malignancies. Lauria F Haematologica; 1992; 77(6):443-5. PubMed ID: 1363233 [No Abstract] [Full Text] [Related]
35. [Hairy cell leukemia, Japanese variant, successfully treated with cladribine]. Miyazaki M; Taguchi A; Sakuragi S; Mitani N; Matsuda K; Shinohara K Rinsho Ketsueki; 2004 May; 45(5):405-7. PubMed ID: 15199752 [TBL] [Abstract][Full Text] [Related]
36. [Failure of treatment with 2-chlorodeoxyadenosine in the course of hairy cell leukemia associated with malignant histiocytosis]. Jullien V; Peyrade F; Taillan B; Perrin C; Sanderson F; Guzman-Granier E; Michiels JF; Dujardin P Rev Med Interne; 1999 Mar; 20(3):287-8. PubMed ID: 10216890 [No Abstract] [Full Text] [Related]
37. Effectiveness of 2-chlorodeoxyadenosine in nodal and extra haematopoietic localizations in hairy cell leukaemia. Rieux C; Bastion Y; Bazin M; Dumontet C; Coiffier B; Felman P; Bryon PA Eur J Haematol; 1995 Aug; 55(2):133-5. PubMed ID: 7628589 [No Abstract] [Full Text] [Related]
38. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Dasanu CA; Alexandrescu DT Expert Opin Pharmacother; 2010 Jan; 11(1):41-50. PubMed ID: 20001428 [TBL] [Abstract][Full Text] [Related]
39. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Ellison DJ; Sharpe RW; Robbins BA; Spinosa JC; Leopard JD; Saven A; Piro LD Blood; 1994 Dec; 84(12):4310-5. PubMed ID: 7994047 [TBL] [Abstract][Full Text] [Related]
40. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. Piro LD; Carrera CJ; Carson DA; Beutler E N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]